Mesenchymal Stem Cell Composition for Thyroid-Associated Ophthalmopathy

Solution Overview

Problem

Current treatments for thyroid-associated ophthalmopathy, such as high concentrations of steroids and radiotherapy, have limited effectiveness and significant side effects, necessitating a novel therapeutic approach.

Innovation Solution

A composition utilizing mesenchymal stem cells that express specific markers like FOXP3, HLA-G, and TLR4, which can be genetically engineered to enhance immune cytokine production and surface antigen expression, is administered to reduce abnormal activity of orbital fibroblasts.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high concentrations of steroids are used for treatment, then anti-inflammatory effect is improved, but side effects increase

Engineering Contradiction:

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces mesenchymal stem cells as an intermediary therapeutic agent that mediates anti-inflammatory effects through immunomodulation and secretion of trophic factors, avoiding the direct toxic effects of high-concentration steroids while achieving comparable or superior therapeutic outcomes in TAO treatment

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If radiotherapy is used for treatment, then tumor control is improved, but harmful effects increase

Engineering Contradiction:

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the physical radiation mechanism with a biological mechanism using mesenchymal stem cells that deliver therapeutic effects through cell-mediated immunomodulation and paracrine signaling, eliminating radiation damage while maintaining therapeutic efficacy

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If orbital decompression surgery is performed, then proptosis relief is improved, but surgical risks increase

Engineering Contradiction:

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs mesenchymal stem cells that autonomously differentiate into functional tissue and secrete growth factors to promote endogenous repair and reduce fibrosis, enabling the orbital tissue to self-regulate and reduce proptosis without requiring surgical intervention and its associated risks

Inventive Principle:

Principle #25Self-service

4Duration of action of stationary object

If conventional treatments are applied, then disease progression is slowed, but treatment limitations persist

Engineering Contradiction:

Core Design Contradiction:

Duration of action of stationary objectVSAdaptability or versatility

Solution Approach 1:

The patent fundamentally changes the therapeutic parameter from chemical/radiological/surgical intervention to cellular therapy, utilizing the dynamic capabilities of mesenchymal stem cells to differentiate, secrete cytokines, and modulate immunity, thereby achieving adaptable and versatile treatment effects that overcome conventional limitations

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP3669884B1Composition for treatment of thyroid associated ophthalmopathy, comprising mesenchymal stem cell

Publication Date: 2023.10.18

Figure 1A
Figure 1B
Figure 2(a)~3A

AI summary

Provided is a composition including mesenchymal stem cells as an effective ingredient for prevention, alleviation, or treatment of thyroid-associated ophthalmopathy. A pharmaceutical composition including mesenchymal stem cells as an effective ingredient for treatment of thyroid-associated ophthalmopathy allows patients with thyroid-associated ophthalmopathy to recover from an abnormal increase in hyaluronic acid production in orbital fibroblasts, increased adipocyte differentiation, and increased lipid accumulation, and thus may be useful for the treatment of thyroid-associated ophthalmopathy.